| HOME >> BIOLOGY >> TECHNOLOGY |
About Key Genomics
Key Genomics works with pharmaceutical and molecular diagnostics companies to improve patient outcomes through new solutions for personalized medicine, drug discovery, and clinical trials by accurately predicting patient response based on cellular assays and patient genomic data. Learn more at http://www.keygenomics.com.
Transgenomic Cautionary Statements
Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements
include, but are not limited to, those with respect to management's current
views and estimates of future economic circumstances, industry conditions,
company performance and financial results, including the ability of the
Company to grow its involvement in the diagnostic products and services
markets. The known risks, uncertainties and other factors affecting these
forward-looking statements are described from time to time in
Transgenomic's reports to the Securities and Exchange Commission. Any
change in such factors, risks and uncertainties may cause the actual
results, events and performance to differ materially from those referred to
in such statements. Accordingly, the company claims the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 with respect to all statements
contained in this press release. All information in this press release is
as of the date of the release and Transgenomic does not undertake any
'/>"/>
| SOURCE Transgenomic Copyright©2008 PR Newswire. All rights reserved |